Noerr advises DUBAG on JPT Peptide acquisition
The LEO III Fund, managed by the Munich-based DUBAG Group, has acquired JPT Peptide Technologies GmbH from BioNTech Diagnostics GmbH. A Noerr team led by Markus A. Braun and Georg Schneider advised DUBAG on the transaction.
The target company
JPT was founded in 2004 as a spin-off from Jerini AG and provides peptide-based research and development solutions. Operating out of Berlin, the company is active across the biopharma, cell and gene therapy, vaccine development, immunology, proteomics and academic research sectors. Under the ownership of the LEO III Fund, JPT will operate as a stand-alone company.
DUBAG Group is an investment advisory team based in Munich that manages private equity funds focused on the acquisition and active development of companies in special situations.
Deal team
The Noerr team advising DUBAG Group was led on the corporate side by Markus A. Braun, associated partner, and Georg Schneider, partner, acting as joint lead, together with John Jun and Teresa Seibold, both senior associates, and Amélie Louisa Bitzer, associate. The real estate workstream was handled by Manuel Lomb, associated partner, and Luca Lowsky, associate, while employment matters were covered by Boris Blunck, partner. Finance advice came from Pinar Turkac-Christmann, associated partner, and public law matters were handled by Hendrik Schlutt, counsel. The regulatory side of the deal was led by Fabian Hübener, partner, and Sven Betzendörfer, senior associate, with tax advice provided by Elmar Bindl, partner, together with Nico Rosenfelder and Maximilian Schischke, both senior associates, and Nicole Wistop, counsel.
